1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Liquid Biopsy Markets, Global Market Size, Strategies and Forecasts 2016 to 2020

“Blood Tests replace Surgical Biopsies. Cancer Screening to create a new multibillion dollar market opportunity .....”

The Diagnostic, Monitoring and Screening opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

What is the size of the huge screening opportunity? They are all listed in Chapter 10.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers.

Table Of Contents

Liquid Biopsy Markets, Global Market Size, Strategies and Forecasts 2016 to 2020
1. Introduction and Market Definition 15
1.1 What is Liquid Biopsy? 16
1.2 The Genetics Revolution 17
1.3 Market Definition 19
1.3.1 Volumes 19
1.3.2 Prices 19
1.3.3 Revenue Market Size 19
1.4 Methodology 20
1.4.1 Authors 20
1.4.2 Sources 21
1.5 Liquid Biopsy and Clinical Laboratory Testing - Spending Perspective 21
1.5.1 U.S. Medicare Expenditures for Clinical Testing 21
2. Market Overview 24
2.1 Market Participants 25
2.1.1 Academic Research Lab 25
2.1.2 Diagnostic Test Developer 25
2.1.3 Genomic Instrumentation Supplier26
2.1.3.1 Cell Separation and Viewing Instrumentation Supplier 26
2.1.4 Pharmaceutical/Reagent Supplier 26
2.1.5 Independent Testing Lab 26
2.1.6 Public National/regional lab 27
2.1.7 Hospital lab 27
2.1.8 Physician Lab 27
2.1.9 Audit Body 27
2.1.10 Certification Body 27
2.2 Conditions Identified with Biopsies 29
2.2.1 Cancer 29
2.2.2 Precancerous conditions 29
2.2.3 Inflammatory condiditons 30
2.3 Biopsy Sites 30
2.4 Analysis of Biopsied Material 31
2.5 Evidence of Cancer - Liquid Biopsy Technology 32
2.5.1 Liquid Biopsy Technology Overview 32
2.5.2 Circulating Tumor Cells 33
2.5.2.1 Types of CTCs 34
2.5.2.2 CellSearch Detection Method 35
2.5.2.3 Epic Sciences Detection Method 35
2.5.2.4 Maintrac Detection Method 36
2.5.2.5 Other Methods 37
2.5.3 Circulating Tumor DNA 37
2.5.4 Exosomes and Micro Vesicles 38
2.6 Changing the Cancer Treatment Protocol 41
2.6.1 Issues and Limitations to Liquid Biopsy Adoption41
2.6.2 The Cancer Screening Market Opportunity 42
2.6.2.1 GRAIL - Exploiting the Screening Opportunity 43
2.6.3 Cancer Management 44
2.6.3.1 Risk Assessment Role In Cancer Management 44
2.6.3.2 Therapy Assessment Role In Cancer Management 44
2.6.3.3 Disease Monitoring Role In Cancer Management 45
2.6.4 Phases of Adoption - Outlook for Usage 45
2.6.5 The Promise of Liquid Biopsy 46
2.7 Industry Structure 48
2.7.1 Hospital Testing Share 48
2.7.2 Economies of Scale 48
2.7.2.1 Hospital vs. Central Lab 48
2.7.3 Physician Office Lab's 49
2.7.4 Physician's and POCT50
2.8 Profiles of Key Liquid Biopsy Companies 51
2.8.1 AdnaGen (now Qiagen)51
2.8.2 Agena Bioscience 52
2.8.3 Angle plc 54
2.8.4 ApoCell 55
2.8.5 Biocept56
2.8.6 BioFluidica 57
2.8.7 Bio-Rad Laboratories 58
2.8.8 Boreal Genomics 60
2.8.10 Chronix Biomedical 61
2.8.11 Clearbridge BioMedics 62
2.8.12 Cynvenio 63
2.8.13 Cytolumina Technologies Corp 64
2.8.14 CytoTrack 65
2.8.15 Diagnologix LLC 66
2.8.16 Epic Sciences 67
2.8.17 Exosome Diagnostics 68
2.8.18 Exosome Sciences 69
2.8.19 Fluidigm Corp 70
2.8.20 Fluxion Biosciences 71
2.8.21 Genomic Health 72
2.8.39 GRAIL 74
2.8.22 Guardant Health 75
2.8.23 HansaBiomed 76
2.8.23 Horizon Discovery 77
2.8.24 iCellate78
2.8.25 Illumina 79
2.8.26 Inivata 80 2.8.27 Janssen Diagnostics 81
2.8.28 Molecular MD 82
2.8.29 Myriad Genetics 83
2.8.30 Natera 84
2.8.31 New Oncology 85
2.8.32 Personal Genome Diagnostics 86
2.8.33 RainDance Technologies 87
2.8.34 Rarecells SAS 88
2.8.35 Silicon Biosystems 89
2.8.36 Sysmex Inostics 90
2.8.37 SRI International 91
2.8.38 Trovagene 92
3. Market Trends 93
3.1 Factors Driving Growth 94
3.1.1 Non Invasive Game Changer 94
3.1.2 Lower Cost 94
3.1.3 Greater Accuracy. 94
3.1.4 Wide Range of Potential Uses 95
3.1.5 Aging Population 95
3.2 Factors Limiting Growth 97
3.2.1 Lower prices 97
3.2.2 Lack of Standards. 97
3.2.3 Protocol Resistance. 97
3.2.4 Initial Adoption Has No Cost Savings 98
3.3 Instrumentation and Automation 99
3.3.1 Instruments Key to Market Share 99
3.3.2 Bioinformatics Plays a Role. 99
3.4 Diagnostic Technology Development100
3.4.1 Next Generation Sequencing Fuels a Revolution. 101
3.4.2 Impact of NGS on pricing 102
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment102
3.4.4 CGES Testing, A Brave New World. 102
3.4.5 Biochips/Giant magneto resistance based assay103
4. Liquid Biopsy Recent Developments104
4.1 Recent Developments - Importance and How to Use This Section 105
4.1.1 Importance of These Developments 105
4.1.2 How to Use This Section 105
4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy105
4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy106
4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study 111
4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen 112
4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test 113
4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options 113
4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab 114
4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance115
4.10 Biocept Q1 Revenues Rise With Test Volume Growth 116
4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers 117
4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood 118
4.13 Cynvenio to present new clinical data118
4.14 EKF, Angle Collaborate for Liquid Biopsy Development 119
4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer120
4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen121
4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics122
4.18 Merck Serono and Sysmex Inostics Announce Testing Center123
4.19 Agena Bioscience Launches Smaller Format MassArray124
4.20 Personal Genome Diagnostics Aims for FDA Clearance 125
4.21 HTG Molecular Diagnostics Files for IPO of up to $60M 125
4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter 127
4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs 128
4.24 Inivata Raises $6.6M to Develop ctDNA Assays 129
4.25 Epic Sciences Raises $30M in Private Financing 129
4.26 New Release in Line of Liquid Biopsy CLIA Tests 130
4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test 131
4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field132
4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test133
4.29 DNA in blood can track cancer development, response in real time134
4.30 Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing 135
4.31 Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay 135
4.32 Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System 137
4.33 MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States138
4.34 GATC Biotech's Liquid Biopsy Testing Takes Cost Lead138
4.35 Liquid Biotech USA, Inc. Announces Completion of Clinical Study139
5. Country Market Sizes - North America 141
5.1 United States of America 142
5.1.1 Lung Cancer Testing - Volumes, Prices, Revenues142
5.1.2 Breast Cancer Testing - Volumes, Prices, Revenues 142
5.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues142
5.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues143
5.1.5 Other Cancer Testing - Volumes, Prices, Revenues143
5.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues143
5.2 Canada 144
5.2.1 Lung Cancer Testing - Volumes, Prices, Revenues144
5.2.2 Breast Cancer Testing - Volumes, Prices, Revenues 144
5.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues144
5.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues145
5.2.5 Other Cancer Testing - Volumes, Prices, Revenues145
5.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues145
6. Country Markets - Europe 146
6.1 France 147
6.1.1 Lung Cancer Testing - Volumes, Prices, Revenues147
6.1.2 Breast Cancer Testing - Volumes, Prices, Revenues 147
6.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues147
6.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues148
6.1.5 Other Cancer Testing - Volumes, Prices, Revenues148
6.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues148
6.2 Germany 149
6.2.1 Lung Cancer Testing - Volumes, Prices, Revenues149
6.2.2 Breast Cancer Testing - Volumes, Prices, Revenues 149
6.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues149
6.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues150
6.2.5 Other Cancer Testing - Volumes, Prices, Revenues150
6.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues150
6.3 United Kingdom 151
6.3.1 Lung Cancer Testing - Volumes, Prices, Revenues151
6.3.2 Breast Cancer Testing - Volumes, Prices, Revenues 151
6.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues151
6.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues152
6.3.5 Other Cancer Testing - Volumes, Prices, Revenues152
6.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues152
6.4 Spain 153
6.4.1 Lung Cancer Testing - Volumes, Prices, Revenues153
6.4.2 Breast Cancer Testing - Volumes, Prices, Revenues 153
6.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues153
6.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues154
6.4.5 Other Cancer Testing - Volumes, Prices, Revenues154
6.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues154
6.5 Italy 155
6.5.1 Lung Cancer Testing - Volumes, Prices, Revenues155
6.5.2 Breast Cancer Testing - Volumes, Prices, Revenues 155
6.5.3 Colorectal Cancer Testing - Volumes, Prices, Revenues155
6.5.4 Prostate Cancer Testing - Volumes, Prices, Revenues156
6.5.5 Other Cancer Testing - Volumes, Prices, Revenues156
6.5.6 All Liquid Biopsy Total - Volumes, Prices, Revenues156
6.6 Russia 157
6.6.1 Lung Cancer Testing - Volumes, Prices, Revenues157
6.6.2 Breast Cancer Testing - Volumes, Prices, Revenues 157
6.6.3 Colorectal Cancer Testing - Volumes, Prices, Revenues157
6.6.4 Prostate Cancer Testing - Volumes, Prices, Revenues158
6.6.5 Other Cancer Testing - Volumes, Prices, Revenues158
6.6.6 All Liquid Biopsy Total - Volumes, Prices, Revenues158
6.7 Remainder of Europe and Former Soviet Union159
6.7.1 Lung Cancer Testing - Volumes, Prices, Revenues159
6.7.2 Breast Cancer Testing - Volumes, Prices, Revenues 159
6.7.3 Colorectal Cancer Testing - Volumes, Prices, Revenues159
6.7.4 Prostate Cancer Testing - Volumes, Prices, Revenues160
6.7.5 Other Cancer Testing - Volumes, Prices, Revenues160
6.7.6 All Liquid Biopsy Total - Volumes, Prices, Revenues160
7. Country Markets - Asia Pacific 161
7.1 China 162
7.1.1 Lung Cancer Testing - Volumes, Prices, Revenues162
7.1.2 Breast Cancer Testing - Volumes, Prices, Revenues 162
7.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues162
7.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues163
7.1.5 Other Cancer Testing - Volumes, Prices, Revenues163
7.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues163
7.2 Japan 164
7.2.1 Lung Cancer Testing - Volumes, Prices, Revenues164
7.2.2 Breast Cancer Testing - Volumes, Prices, Revenues 164
7.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues164
7.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues165
7.2.5 Other Cancer Testing - Volumes, Prices, Revenues165
7.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues165
7.3 South Korea 166
7.3.1 Lung Cancer Testing - Volumes, Prices, Revenues166
7.3.2 Breast Cancer Testing - Volumes, Prices, Revenues 166
7.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues166
7.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues167
7.3.5 Other Cancer Testing - Volumes, Prices, Revenues167
7.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues167
7.4 India 168
7.4.1 Lung Cancer Testing - Volumes, Prices, Revenues168
7.4.2 Breast Cancer Testing - Volumes, Prices, Revenues 168
7.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues168
7.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues169
7.4.5 Other Cancer Testing - Volumes, Prices, Revenues169
7.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues169
7.5 Australia 170
7.5.1 Lung Cancer Testing - Volumes, Prices, Revenues170
7.5.2 Breast Cancer Testing - Volumes, Prices, Revenues 170
7.5.3 Colorectal Cancer Testing - Volumes, Prices, Revenues170
7.5.4 Prostate Cancer Testing - Volumes, Prices, Revenues171
7.5.5 Other Cancer Testing - Volumes, Prices, Revenues171
7.5.6 All Liquid Biopsy Total - Volumes, Prices, Revenues171
7.6 Rest of Asia Pacific 172
7.6.1 Lung Cancer Testing - Volumes, Prices, Revenues172
7.6.2 Breast Cancer Testing - Volumes, Prices, Revenues 172
7.6.3 Colorectal Cancer Testing - Volumes, Prices, Revenues172
7.6.4 Prostate Cancer Testing - Volumes, Prices, Revenues173
7.6.5 Other Cancer Testing - Volumes, Prices, Revenues173
7.6.6 All Liquid Biopsy Total - Volumes, Prices, Revenues173
8. Country Markets - Latin America, Africa and The Middle East 174
8.1 Brazil 175
8.1.1 Lung Cancer Testing - Volumes, Prices, Revenues175
8.1.2 Breast Cancer Testing - Volumes, Prices, Revenues 175
8.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues175
8.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues176
8.1.5 Other Cancer Testing - Volumes, Prices, Revenues176
8.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues176
8.2 Mexico 177
8.2.1 Lung Cancer Testing - Volumes, Prices, Revenues177
8.2.2 Breast Cancer Testing - Volumes, Prices, Revenues 177
8.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues177
8.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues178
8.2.5 Other Cancer Testing - Volumes, Prices, Revenues178
8.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues178
8.3 Rest of Latin America 179
8.3.1 Lung Cancer Testing - Volumes, Prices, Revenues179
8.3.2 Breast Cancer Testing - Volumes, Prices, Revenues 179
8.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues179
8.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues180
8.3.5 Other Cancer Testing - Volumes, Prices, Revenues180
8.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues180
8.4 Africa and The Middle East 181
8.4.1 Lung Cancer Testing - Volumes, Prices, Revenues181
8.4.2 Breast Cancer Testing - Volumes, Prices, Revenues 181
8.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues181
8.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues182
8.4.5 Other Cancer Testing - Volumes, Prices, Revenues182
8.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues182
9. Global Market Summary 183
9.1 Global 184
9.1.1 Lung Cancer Testing - Volumes, Prices, Revenues184
9.1.2 Breast Cancer Testing - Volumes, Prices, Revenues 184
9.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues184
9.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues185
9.1.5 Other Cancer Testing - Volumes, Prices, Revenues185
9.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues185
10. Potential Market Opportunity Sizes 186
10.1 Cancer Screening by Country: Lung, Breast and Colorectal187
10.2 Cancer Screening by Country: Prostate, Other Cancer and All Cancer188
10.3 Potential Market Size - Cancer Diagnosis189
10.4 Potential Market Size - Cancer Management 190

Appendices 191
I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint 191
II. FDA Approved Human Genetic Tests 223
III. FDA Approved Pharmacogenomics Tests226

Table of Tables
Table 1 Medicare Clinical Lab Expenditures Actual and Forecast 2004 to 2020 ($Billion) 23
Table 2 Market Players by Type 25
Table 3 Biopsy Sites30
Table 4 Advantages of Liquid Biopsy in Screening Market43
Table 5 Five Factors Driving Growth94
Table 6 Four Factors Limiting Growth97
Table 7 Key Diagnostic Laboratory Technology Trends 100
Table 8 Next Generation Sequencing Technologies - Speed and Cost 101
Table 9 Lung Cancer Testing - Volume Price and Revenue Forecast142
Table 10 Breast Cancer Testing - Volume Price and Revenue Forecast 142
Table 11 Colorectal Cancer Testing - Volume Price and Revenue Forecast 142
Table 12 Prostate Cancer Testing - Volume Price and Revenue Forecast 143
Table 13 Other Cancer Testing - Volume Price and Revenue Forecast143
Table 14 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 143
Table 15 Lung Cancer Testing - Volume Price and Revenue Forecast144
Table 16 Breast Cancer Testing - Volume Price and Revenue Forecast 144
Table 17 Colorectal Cancer Testing - Volume Price and Revenue Forecast 144
Table 18 Prostate Cancer Testing - Volume Price and Revenue Forecast 145
Table 19 Other Cancer Testing - Volume Price and Revenue Forecast145
Table 20 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 145
Table 21 Lung Cancer Testing - Volume Price and Revenue Forecast147
Table 22 Breast Cancer Testing - Volume Price and Revenue Forecast 147
Table 23 Colorectal Cancer Testing - Volume Price and Revenue Forecast 147
Table 24 Prostate Cancer Testing - Volume Price and Revenue Forecast 148
Table 25 Other Cancer Testing - Volume Price and Revenue Forecast148
Table 26 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 148
Table 27 Lung Cancer Testing - Volume Price and Revenue Forecast149
Table 28 Breast Cancer Testing - Volume Price and Revenue Forecast 149
Table 29 Colorectal Cancer Testing - Volume Price and Revenue Forecast 149
Table 30 Prostate Cancer Testing - Volume Price and Revenue Forecast 150
Table 31 Other Cancer Testing - Volume Price and Revenue Forecast150
Table 32 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 150
Table 33 Lung Cancer Testing - Volume Price and Revenue Forecast151
Table 34 Breast Cancer Testing - Volume Price and Revenue Forecast 151
Table 35 Colorectal Cancer Testing - Volume Price and Revenue Forecast 151
Table 36 Prostate Cancer Testing - Volume Price and Revenue Forecast 152
Table 37 Other Cancer Testing - Volume Price and Revenue Forecast152
Table 38 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 152
Table 39 Lung Cancer Testing - Volume Price and Revenue Forecast153
Table 40 Breast Cancer Testing - Volume Price and Revenue Forecast 153
Table 41 Colorectal Cancer Testing - Volume Price and Revenue Forecast 153
Table 42 Prostate Cancer Testing - Volume Price and Revenue Forecast 154
Table 43 Other Cancer Testing - Volume Price and Revenue Forecast154
Table 44 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 154
Table 45 Lung Cancer Testing - Volume Price and Revenue Forecast155
Table 46 Breast Cancer Testing - Volume Price and Revenue Forecast 155
Table 47 Colorectal Cancer Testing - Volume Price and Revenue Forecast 155
Table 48 Prostate Cancer Testing - Volume Price and Revenue Forecast 156
Table 49 Other Cancer Testing - Volume Price and Revenue Forecast156
Table 50 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast156
Table 51 Lung Cancer Testing - Volume Price and Revenue Forecast157
Table 52 Breast Cancer Testing - Volume Price and Revenue Forecast 157
Table 53 Colorectal Cancer Testing - Volume Price and Revenue Forecast 157
Table 54 Prostate Cancer Testing - Volume Price and Revenue Forecast 158
Table 55 Other Cancer Testing - Volume Price and Revenue Forecast158
Table 56 All Liquid Biopsy - Volume Price and Revenue Forecast158
Table 57 Lung Cancer Testing - Volume Price and Revenue Forecast159
Table 58 Breast Cancer Testing - Volume Price and Revenue Forecast 159
Table 59 Colorectal Cancer Testing - Volume Price and Revenue Forecast 159
Table 60 Prostate Cancer Testing - Volume Price and Revenue Forecast 160
Table 61 Other Cancer Testing - Volume Price and Revenue Forecast160
Table 62 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 160
Table 63 Lung Cancer Testing - Volume Price and Revenue Forecast162
Table 64 Breast Cancer Testing - Volume Price and Revenue Forecast 162
Table 65 Colorectal Cancer Testing - Volume Price and Revenue Forecast 162
Table 66 Prostate Cancer Testing - Volume Price and Revenue Forecast 163
Table 67 Other Cancer Testing - Volume Price and Revenue Forecast163
Table 68 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 163
Table 69 Lung Cancer Testing - Volume Price and Revenue Forecast164
Table 70 Breast Cancer Testing - Volume Price and Revenue Forecast 164
Table 71 Colorectal Cancer Testing - Volume Price and Revenue Forecast 164
Table 72 Prostate Cancer Testing - Volume Price and Revenue Forecast 165
Table 73 Other Cancer Testing - Volume Price and Revenue Forecast165
Table 74 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 165
Table 75 Lung Cancer Testing - Volume Price and Revenue Forecast166
Table 76 Breast Cancer Testing - Volume Price and Revenue Forecast 166
Table 77 Colorectal Cancer Testing - Volume Price and Revenue Forecast 166
Table 78 Prostate Cancer Testing - Volume Price and Revenue Forecast 167
Table 79 Other Cancer Testing - Volume Price and Revenue Forecast167
Table 80 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 167
Table 81 Lung Cancer Testing - Volume Price and Revenue Forecast168
Table 82 Breast Cancer Testing - Volume Price and Revenue Forecast 168
Table 83 Colorectal Cancer Testing - Volume Price and Revenue Forecast 168
Table 84 Prostate Cancer Testing - Volume Price and Revenue Forecast 169
Table 85 Other Cancer Testing - Volume Price and Revenue Forecast169
Table 86 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 169
Table 87 Lung Cancer Testing - Volume Price and Revenue Forecast170
Table 88 Breast Cancer Testing - Volume Price and Revenue Forecast 170
Table 89 Colorectal Cancer Testing - Volume Price and Revenue Forecast 170
Table 90 Prostate Cancer Testing - Volume Price and Revenue Forecast 171
Table 91 Other Cancer Testing - Volume Price and Revenue Forecast171
Table 92 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast171
Table 93 Lung Cancer Testing - Volume Price and Revenue Forecast172
Table 94 Breast Cancer Testing - Volume Price and Revenue Forecast 172
Table 95 Colorectal Cancer Testing - Volume Price and Revenue Forecast 172
Table 96 Prostate Cancer Testing - Volume Price and Revenue Forecast 173
Table 97 Other Cancer Testing - Volume Price and Revenue Forecast173
Table 98 All Liquid Biopsy - Volume Price and Revenue Forecast173
Table 99 Lung Cancer Testing - Volume Price and Revenue Forecast175
Table 100 Breast Cancer Testing - Volume Price and Revenue Forecast 175
Table 101 Colorectal Cancer Testing - Volume Price and Revenue Forecast 175
Table 102 Prostate Cancer Testing - Volume Price and Revenue Forecast 176
Table 103 Other Cancer Testing - Volume Price and Revenue Forecast176
Table 104 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 176
Table 105 Lung Cancer Testing - Volume Price and Revenue Forecast177
Table 106 Breast Cancer Testing - Volume Price and Revenue Forecast 177
Table 107 Colorectal Cancer Testing - Volume Price and Revenue Forecast 177
Table 108 Prostate Cancer Testing - Volume Price and Revenue Forecast 178
Table 109 Other Cancer Testing - Volume Price and Revenue Forecast178
Table 110 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 178
Table 111 Lung Cancer Testing - Volume Price and Revenue Forecast179
Table 112 Breast Cancer Testing - Volume Price and Revenue Forecast 179
Table 113 Colorectal Cancer Testing - Volume Price and Revenue Forecast 179
Table 114 Prostate Cancer Testing - Volume Price and Revenue Forecast 180
Table 115 Other Cancer Testing - Volume Price and Revenue Forecast180
Table 116 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 180
Table 117 Lung Cancer Testing - Volume Price and Revenue Forecast181
Table 118 Breast Cancer Testing - Volume Price and Revenue Forecast 181
Table 119 Colorectal Cancer Testing - Volume Price and Revenue Forecast 181
Table 120 Prostate Cancer Testing - Volume Price and Revenue Forecast 182
Table 121 Other Cancer Testing - Volume Price and Revenue Forecast182
Table 122 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 182
Table 123 Lung Cancer Testing - Volume Price and Revenue Forecast184
Table 124 Breast Cancer Testing - Volume Price and Revenue Forecast 184
Table 125 Colorectal Cancer Testing - Volume Price and Revenue Forecast 184
Table 126 Prostate Cancer Testing - Volume Price and Revenue Forecast 185
Table 127 Other Cancer Testing - Volume Price and Revenue Forecast185
Table 128 All Liquid Biopsy Testing - Volume Price and Revenue Forecast 185
Table 129 Potential Screening Market: Lung, Breast and Colorectal 187
Table 130 Potential Screening Market: Prostate, Other and All1 88
Table 131 Potential Cancer Diagnosis Market Size 189
Table 132 Potential Cancer Management Market Size 190
Table 133 2015 Clinical Lab Fee Schedule 191

Table of Figures
Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million) 22
Figure 2 Comparison of Liquid Biopsy Classes 33
Figure 3 Characteristics of Different Vesicle Types 41
Figure 4 Percentage of World Population Over 65 95

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.